• Derma Sciences Inc., of Princeton, N.J., said it closed its public offering of about 3.5 million shares priced at $10.34 apiece, including the exercise of the underwriters' option to purchase 459,300 shares to cover overallotments. Net proceeds totaled about $33.8 million and will be used to support continued development of DSC127 for the treatment of diabetic foot ulcers, as well as for general corporate purposes.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST